Long-term Prognosis of Patients With Sepsis After Immunotherapy
- Conditions
- Long-term Effects of Thymosin Alpha 1 Treatment
- Interventions
- Registration Number
- NCT04901104
- Lead Sponsor
- Sun Yat-sen University
- Brief Summary
Current clinical studies of thymosin α1 for sepsis have focused on short-term outcomes (28-day or 90-day mortality), and lack of clinical data on long-term outcomes (3 year mortality) of patients with sepsis after immunotherapy.
Based on the preliminary clinical study (NCT02867267), this study will conduct long-term follow-up for sepsis patients to provide data support for the long-term prognosis of immunotherapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 900
- Sepsis patients in the TESTS study Patients who discharged from hospital after recovery
- None
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description thymosin α1 group Thymosin Alpha1 The patient was treated with thymosin α1 in sepsis
- Primary Outcome Measures
Name Time Method three years mortality 3 years Mortality rate of patients treated with thymosin α1 or placebo within 3 years
- Secondary Outcome Measures
Name Time Method Recurrence rate of sepsis 5 years Percentage of recurrent sepsis within 5 years of discharge sepsis patients
Five years mortality 5 years Mortality rate of patients treated with thymosin α1 or placebo within 5 years
short form 36 questionnaire 1 year Quality of life of sepsis patients after 1 year of thymosin α1 or placebo treatment
one year mortality 1 year Mortality rate of patients treated with thymosin α1 or placebo within 1 year